EGFR and breast carcinoma: Nuclear EGFR correlates with poor outcomes in multiple human malignancies, including breast cancer [25], ovarian cancer [26], non-small cell lung cancer (NSCLC) [27], and oropharyngeal squamous carcinoma [28].